We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Share this :
Print
GenScript MonoRab™ Anti-Ocrelizumab Antibody (15E7), mAb, Rabbit
Genscript MonoRab™ Anti-Ocrelizumab Antibody (15E7), mAb, Rabbit - GSCRPT (Additional S&H or Hazmat Fees May Apply)
List Price
$144.00
Your Price
$144.00
HOW MUCH YOU SAVE:
0.00 %
| NETA PART: | GSCRPT-A02259-40 |
| MFG.PART: | A02259-40 |
| UNSPSC: | 12352203 |
| Manufacturer: | GenScript USA Inc |
Overview
| Specificity | This product is specific for Ocrelizumab. |
| Host Species | Rabbit |
| Immunogen | Ocrelizumab |
| Conjugate | Unconjugated |
Applications
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
| |||||||||
Properties
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for up to 1 year at -20 °C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification | Protein A affinity column |
| Isotype | Rabbit IgG, κ |
| Clonality | Monoclonal |
| Clone ID | 15E7 |
| Note | GenScript can customize this product per customers request including product size, buffer components, etc. |
Background
| Target Background | Ocrelizumab is a recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells expressing the CD20 antigen. It is indicated for the treatment of primary progressive or relapsing forms of multiple sclerosis (MS). Compared to non-humanized CD20 antibodies like rituximab, ocrelizumab is anticipated to have a lower potential for immunogenicity with repeated infusions. This improved benefit-to-risk profile is beneficial for patients with MS. |
| Synonyms | Ocrelizumab; OCREVUS; Ocrevus; |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
| SKU | GSCRPT-A02259-40 |
|---|---|
| Supplier Part Number | A02259-40 |
| UM | EA |
| UNSPSC | 12352203 |
| Manufacturer | GenScript USA Inc |
| ProductLine | GSCRPT |
| Qty | 40 |
| MinOrderQty | 1 |
| Weight | 7.00 |
| Lead Time | 7 Business Days |
| Hazardous | N |